country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189876

Copy Link Print Information

Anticancer agent-368

Anticancer agent-368 is an isoxazole-1,2,3-triazole hybrid derivative with anticancer activity. Anticancer agent-368 exhibits in vitro antiproliferative activity against HepG2 hepatocellular carcinoma cells and can cause tumor cell membrane damage. Molecular docking prediction results of Anticancer agent-368 show that it can bind to Hsp90-β. Anticancer agent-368 can be used in research related to hepatocellular carcinoma.

For research use only. We do not sell to patients.

Formula: C₂₀H₁₈N₄O₄
Molecular Weight:378.38

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Anticancer agent-368 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC50	0.433 mg/mL	Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 24 hrs by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 24 hrs by MTT assay.	42097518
HepG2	IC50	0.401 mg/mL	Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42097518
HepG2	IC50	0.378 mg/mL	Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 72 hrs by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 72 hrs by MTT assay.	42097518
HepG2	IC50	0.627 mg/mL	Antiproliferative activity against human HepG2 cells assessed as viability reduction by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction by MTT assay.	42097518

In Vitro

Anti-cancerBacterial InfectionOthers

Anti-cancer

Anticancer agent-368 (compound 4c) (0.1-0.5 mg/mL; 24-72 h) exhibits moderate concentration- and time-dependent antiproliferative activity against HepG2 cells, with high LDH release at 0.5 mg/mL^[1].

Bacterial Infection

Anticancer agent-368 produces no detectable growth inhibition against any of the tested Gram-positive and Gram-negative bacterial strains^[1].

Others

Anticancer agent-368 is predicted by the model to target Hsp90‑β with 99% probability, with a molecular docking score of ‑12.5 kcal/mol^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

0.1, 0.2, 0.3, 0.4, and 0.5 mg/mL
Incubation Time:

24, 48, 72 h
Result:

Displayed moderate concentration- and time-dependent antiproliferative activity against HepG2 cells, with IC₅₀ values of 0.433, 0.401, and 0.378 mg/mL at 24, 48, and 72 h.

Related Protocols :

Chemical Information

Molecular Weight 378.38
Formula C₂₀H₁₈N₄O₄
SMILES

OC1=CC=C(CN2N=NC(COCC3=CC(C4=CC=C(O)C=C4)=NO3)=C2)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Hazarika PK, et al. Development of isoxazole tethered 1,2,3-triazoles and sulphonamide derivatives as potent anti-bacterial and anti-cancer agents. Bioorganic & medicinal chemistry letters. 2026 Sep;138:130681.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote